The enhancer activity was partially mediated by AP-1, with lower expression of JUN and FOS in lungs from patients with IPF compared to controls and lower binding of JUN to the enhancer region in IPF fibroblasts. Here, JUN is linked to idiopathic pulmonary fibrosis.